

Tentative Outline

Special Thematic Issue for the journal

Title of the Thematic Issue: Cannabis based medicinal products extraction and application in Medicine

Guest Editor: Professor Alexander Seifalian, NanoRegMed Ltd, London, UK
Professor Ash Mosahebi, Plastic Surgery, UCL, London UK

- **Scope of the Thematic Issue:**

Cannabis based products for medicinal use in humans (CBPMs) have a promising future in the field of pharmaceutical therapeutics. CBPMs are composed of phytocannabinoids of which the two most abundant are known as delta-9-tetrahydrocannabinol (THC), cannabidiol (CBD). CBPMs are assessed on the concentration ratios of THC versus CBD. THC is a psychoactive compound and therefore minimal or negligible concentrations of this are desired. There are multiple methods of processing CBPMs with availability in the form of flowers or oils. Production of oils can be via CO₂ extractions systems, known to be safer and purer but more expensive, as well as solvent chemical extraction, which is a cheap process that results in traces of harmful chemicals. In order for doctors to confidently prescribe CBPMs, there needs to be more transparency in the method of production of available products and chemical composition.

Regulation's policy is rapidly changing around the world for application of CBPMs for treatment of diseases and pain relief. Regulations in the UK recently relaxed in 2019 to allow doctors on the specialist register to dispense private prescriptions of CBPMs however in reality this has not resulted in the surge in CBPM use that was expected. Confidence amongst doctors in prescribing CBPMs remains an issue as use remains unlicensed and information regarding purity and dosage regimens remains limited. There are several applications currently under research, from pain management to anticancer therapy. Currently, the NHS provides prescriptions for exceptional cases in refractory epilepsy in children when all conventional therapies have been exhausted. As the rules relax around prescription of CBPMs to treat medical diseases, there is hope that research may accelerate in this field, harnessing the properties of cannabis as a natural extract to treat and cure diseases in a safe and effective way.

The application of CBPMs in medicine has significantly increased, shown with significant increase in publication as well as clinical trials on the patients.

Keywords: 6 to 8 keywords should be provided. Cannabidiol, CBD, pain, cancer, neurological diseases,

Sub-topics:

The sub-topics to be covered within the issue should be provided:

Contributions are invited on, but not restricted to, the following themes:

- Method of production of CBPMs and standardization
- Biochemical process of the endocannabinoid system
- Cannabinoid receptors and signalling
- Long-term effects on the brain
- Toxicological studies
- Cancer treatment

- Optimal dosing and drug delivery
- Regulation and ethics.
- Basic research on CBPMs in vitro and in vivo
- Clinical trial of CBPMs.
- Research papers
- Review papers

Tentative titles of the articles and list of contributors:

Tentative titles of the articles and list of contributors with their names, designations, addresses and email addresses should be provided.

PLEASE ADVERTISE AND WE WILL START INVITING CONTRIBUTION.

Schedule:

- ✧ Thematic issue submission deadline: 31 December 2022

Contacts:

Guest Editor: Professor Alexander Seifalian, NanoRegMed Ltd, London, UK, a.seifalian@gmail.com

Professor Ash Mosahebi, Plastic Surgery, UCL, London UK, ashmosahebi@gmail.com